#USA #San Jose #Hyundai Bioscience #XAFTY #Free Drug Supply

Hyundai Bioscience USA Joins the Fight Against Ebola

Hyundai Bioscience USA has made a significant commitment to global health by offering its broad-spectrum antiviral drug, XAFTY® (CP-COV03), free of charge for clinical trials and emergency use in countries facing Ebola outbreaks. This initiative comes in response to the pressing need for effective treatments during the current Ebola crisis in Africa.

A Response to Urgent Needs

On June 10, 2026, the company announced its pledge based on a proposal from Dr. Davey Smith, a prominent infectious disease expert at the University of California, San Diego. Dr. Smith emphasized the need for rapid testing of potential therapies for Ebola, which he viewed as an urgent public health crisis. He noted that XAFTY® should be evaluated quickly to determine its effectiveness against the lethal virus, especially since lab testing has indicated its potency against Ebola is stronger than that against COVID-19.

Rapid Testing Under WHO Guidelines

The World Health Organization (WHO) has established guidelines for the emergency use of unapproved interventions, known as the Monitored Emergency Use of Unregistered and Experimental Interventions (MEURI) framework. Under these rules, XAFTY® meets the requirements for immediate testing due to its established human safety profile, allowing for pre-emptive administration even before formal approval or clinical trials, should an epidemic arise without effective alternatives.

Commitment to Supporting Clinical Trials

In addition to supplying the drug free of charge, Hyundai Bioscience USA has agreed to fund the clinical trials necessary to evaluate XAFTY® in the context of Ebola treatment. Dr. Smith requested this support to help expedite the process, which can often be delayed due to bureaucratic hurdles and funding issues in the midst of a health crisis. The company's willingness to bear these costs underlines its commitment to public health and emergency preparedness.

A Broad-Spectrum Solution

XAFTY® is designed not just to target COVID-19 but serves as a universal antiviral capable of addressing various viral threats including those not yet identified. This approach stems from the lessons learned during the COVID-19 pandemic, where rapid developments in therapeutics underscored the importance of having versatile antiviral options ready for deployment.

Proven Efficacy and Safety

According to recent studies, XAFTY® exhibits significant antiviral activity against a wide range of viruses, backed by previous successful trials involving over 300 participants suffering from COVID-19. The data suggests that XAFTY® can inhibit Ebola virus replication at lower concentrations than those required for COVID-19, making it a promising candidate for urgent testing in affected regions.

Voices from the Field

Jason Kim, President of Hyundai Bioscience USA, expressed the urgency of providing effective treatments for high-fatality diseases like Ebola without the delays typically associated with drug release processes. He stated, "In high-fatality diseases such as Ebola, treatment opportunities must not be missed because of procedures and costs. We are committed to saving lives through immediate action."

In collaboration with the WHO and local health authorities, Hyundai Bioscience USA aims to mobilize XAFTY® to those in need swiftly. The company holds its stock of XAFTY® prepared to distribute as necessary once approvals are secured, ensuring rapid access to this invaluable resource during critical times.

Conclusion

Hyundai Bioscience USA’s proactive stance in providing XAFTY® free of charge marks a significant step in addressing the current Ebola crisis. By leveraging scientific expertise and committing to rapid clinical trials, the company not only seeks to contribute to emergency responses but also envisions a future where a universal antiviral can mitigate the effects of emerging viral threats globally.